pyrazines has been researched along with bmn 673 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arthur, G; Bebb, DG; Bolyos, A; Bose, P; Goutam, S; Jette, NR; Lees-Miller, SP; Petersen, LF; Radhamani, S; Ye, R | 1 |
| Amthor, B; Blattmann, C; Heidler, CL; Huber, PE; Kovac, M; Kulozik, AE; Neu-Yilik, G; Perez, RL; Roth, EK; Thiemann, M | 1 |
2 other study(ies) available for pyrazines and bmn 673
| Article | Year |
|---|---|
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Gene Deletion; Histones; Humans; Lung Neoplasms; Mutation; Nitroso Compounds; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrimidines; RNA, Messenger; Sulfones; Tumor Suppressor Protein p53 | 2019 |
Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Clone Cells; Drug Synergism; Humans; Mice; Osteosarcoma; Phthalazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays | 2020 |